{"id":15436,"date":"2026-10-30T11:59:52","date_gmt":"2026-10-30T11:59:52","guid":{"rendered":"https:\/\/www.incredmoney.com\/blog\/?p=15436"},"modified":"2026-11-03T08:33:24","modified_gmt":"2026-11-03T08:33:24","slug":"sun-pharmaceutical-industries-quarterly-results-fy27","status":"publish","type":"post","link":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/","title":{"rendered":"Sun Pharma Q2 FY27 Results: Revenue, Profit, Sales & Key Updates"},"content":{"rendered":"

Sun Pharma Q2 FY27 Results: Revenue, Profit, Sales & Key Updates<\/h1>\n

Sun Pharmaceutical Industries reported consolidated revenue from operations of \u20b916,198.71 crore in Q2 FY27, up 11.9% year on year (YoY). Consolidated net profit declined 36.2% to \u20b91,988.53 crore, compared with \u20b93,117.95 crore in the corresponding quarter of the previous financial year. The quarter ended on 30 September 2026.<\/p>\n

Sun Pharma\u2019s Q2 FY27 Earnings<\/h2>\n
\n\n\n\n\n\n\n
Financial Metric<\/th>\nQ2 FY27<\/th>\nQ2 FY26<\/th>\nYoY Change<\/th>\n<\/tr>\n<\/thead>\n
Consolidated revenue from operations<\/td>\n\u20b916,198.71 crore<\/td>\n\u20b914,478.31 crore<\/td>\n+11.9%<\/td>\n<\/tr>\n
Consolidated net profit (PAT)<\/td>\n\u20b91,988.53 crore<\/td>\n\u20b93,117.95 crore<\/td>\n-36.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Sun Pharma<\/a> reported exceptional expenses of \u20b91,268.8 crore during the quarter. These included expenses related to the proposed acquisition of Organon and the settlement of US generic pharmaceuticals pricing antitrust litigation. The charges contributed to the decline in reported net profit.<\/p>\n

Business Performance & Key Metrics<\/h2>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Operating Metric<\/th>\nQ2 FY27<\/th>\nPrevious Period \/ Reference<\/th>\n<\/tr>\n<\/thead>\n
Consolidated revenue from operations<\/td>\n\u20b916,198.71 crore<\/td>\n+11.9% YoY<\/td>\n<\/tr>\n
Consolidated net profit<\/td>\n\u20b91,988.53 crore<\/td>\n-36.2% YoY<\/td>\n<\/tr>\n
Adjusted net profit<\/td>\n\u20b93,162 crore<\/td>\n+1.4% YoY<\/td>\n<\/tr>\n
EBITDA<\/td>\n\u20b94,744 crore<\/td>\n+4.8% YoY<\/td>\n<\/tr>\n
EBITDA margin<\/td>\n29.3%<\/td>\n31.3% in Q2 FY26<\/td>\n<\/tr>\n
India formulations sales<\/td>\n\u20b95,552.3 crore<\/td>\n+17.3% YoY<\/td>\n<\/tr>\n
US formulations sales<\/td>\nUS$455 million<\/td>\n-8.2% YoY<\/td>\n<\/tr>\n
Emerging markets formulations sales<\/td>\nUS$350 million<\/td>\n+7.6% YoY<\/td>\n<\/tr>\n
Research and development expenditure<\/td>\n\u20b9778.4 crore<\/td>\n4.8% of sales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Sun Pharma\u2019s domestic formulations business recorded growth of 17.3%, while emerging markets sales increased 7.6%. US formulations\u2019 sales declined 8.2% year on year. Research and development expenditure stood at \u20b9778.4 crore during the quarter.<\/p>\n

Share Price Reaction After Q2 FY27 Results<\/h2>\n
\n\n\n\n\n\n\n\n\n\n\n\n
Results Metric<\/th>\nValue<\/th>\n<\/tr>\n<\/thead>\n
Results announcement date<\/td>\n30 October 2026<\/td>\n<\/tr>\n
Consolidated PAT<\/td>\n\u20b91,988.53 crore<\/td>\n<\/tr>\n
PAT growth YoY<\/td>\n-36.2%<\/td>\n<\/tr>\n
Revenue growth YoY<\/td>\n+11.9%<\/td>\n<\/tr>\n
Share price during afternoon trade (BSE)<\/td>\n\u20b91,833.30<\/td>\n<\/tr>\n
Share price movement<\/td>\n+3.99%<\/td>\n<\/tr>\n
Earnings call<\/td>\n6:30 PM IST, 30 October 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Sun Pharma’s shares gained during afternoon trade on 30 October 2026 despite the decline in reported net profit. The company’s revenue growth, domestic formulations performance and adjusted profitability were among the factors investors considered. The management’s earnings call was scheduled for 6:30 PM IST on the results announcement date. Investors will focus on domestic and international sales, EBITDA margins, research and development expenditure, exceptional costs and the proposed Organon acquisition in the management commentary.<\/p>\n

Sun Pharma vs Other Pharmaceutical Stocks<\/h2>\n
\n\n\n\n\n\n\n\n\n
Company<\/th>\nRevenue \/ Total Income (Q2 FY27)<\/th>\nPAT (Q2 FY27)<\/th>\nPAT Growth YoY<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma<\/a><\/td>\n\u20b916,198.71 crore (consolidated revenue from operations)<\/td>\n\u20b91,988.53 crore (consolidated)<\/td>\n-36.2%<\/td>\n<\/tr>\n
Cipla<\/a><\/td>\nResults awaited<\/td>\nResults awaited<\/td>\n\u2014<\/td>\n<\/tr>\n
Dr. Reddy’s Laboratories<\/a><\/td>\nResults awaited<\/td>\nResults awaited<\/td>\n\u2014<\/td>\n<\/tr>\n
Divi’s Laboratories<\/a><\/td>\nResults awaited<\/td>\nResults awaited<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Sun Pharma\u2019s Quarterly Financial Performance<\/h2>\n
\n\n\n\n\n\n\n\n
Quarter<\/th>\nRevenue from Operations<\/th>\nPAT<\/th>\nGrowth Highlight<\/th>\n<\/tr>\n<\/thead>\n
Q2 FY27<\/td>\n\u20b916,198.71 crore (consolidated)<\/td>\n\u20b91,988.53 crore (consolidated)<\/td>\nRevenue +11.9% YoY; PAT -36.2% YoY<\/td>\n<\/tr>\n
Q1 FY27<\/td>\n\u20b915,299.9 crore (consolidated)<\/td>\n\u20b92,901 crore (consolidated)<\/td>\nRevenue +10.5% YoY; PAT +27% YoY<\/td>\n<\/tr>\n
Q2 FY26<\/td>\n\u20b914,478.31 crore (consolidated)<\/td>\n\u20b93,117.95 crore (consolidated)<\/td>\nBase quarter for YoY comparison<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Sun Pharma reported sequential growth in consolidated revenue from operations in Q2 FY27 compared with Q1 FY27. However, reported PAT declined sequentially and year on year, reflecting the impact of exceptional items. The adjusted net profit of \u20b93,162 crore provides an additional reference point for assessing the quarter’s underlying profitability.<\/p>\n

Key Takeaways from Sun Pharma Q2 FY27 Results<\/h2>\n
    \n
  • Consolidated revenue from operations:<\/strong> \u20b916,198.71 crore, up 11.9% YoY.<\/li>\n
  • Consolidated PAT:<\/strong> \u20b91,988.53 crore, down 36.2% YoY.<\/li>\n
  • Adjusted net profit:<\/strong> \u20b93,162 crore, up 1.4% YoY.<\/li>\n
  • EBITDA:<\/strong> \u20b94,744 crore, up 4.8% YoY.<\/li>\n
  • EBITDA margin:<\/strong> 29.3%, compared with 31.3% in Q2 FY26.<\/li>\n
  • India formulations\u2019 sales:<\/strong> \u20b95,552.3 crore, up 17.3% YoY.<\/li>\n
  • US formulations sales:<\/strong> US$455 million, down 8.2% YoY.<\/li>\n
  • Emerging markets formulations sales:<\/strong> US$350 million, up 7.6% YoY.<\/li>\n
  • Research and development expenditure:<\/strong> \u20b9778.4 crore, representing 4.8% of sales.<\/li>\n
  • Exceptional items:<\/strong> \u20b91,269 crore, largely comprising a US generic-pricing antitrust litigation settlement and Organon acquisition-related costs.<\/li>\n
  • Key metrics to track:<\/strong> domestic and international sales growth, EBITDA margins, research and development expenditure, exceptional costs, adjusted profitability, and progress on the Organon acquisition.<\/li>\n<\/ul>\n
    \n

    Disclaimer<\/h2>\n

    The information provided above is for informational and educational purposes only and should not be construed as investment advice, a recommendation to buy or sell Sun Pharma shares, or a guarantee of future performance. The financial results, operational metrics and peer comparisons are based on information available as of 30 October 2026 and may be subject to revisions or updates. Investors should refer to Sun Pharma\u2019s official disclosures, investor presentation and BSE\/NSE filings for the latest information.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Sun Pharma Q2 FY27 Results: Revenue, Profit, Sales & Key Updates Sun Pharmaceutical Industries reported consolidated revenue from operations of \u20b916,198.71 crore in Q2 FY27, up 11.9% year on year (YoY). Consolidated net profit declined 36.2% to \u20b91,988.53 crore, compared with \u20b93,117.95 crore in the corresponding quarter of the previous financial year. The quarter ended […]<\/p>\n","protected":false},"author":9,"featured_media":15457,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[65],"tags":[2],"class_list":["post-15436","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-quarterly-results","tag-blog"],"acf":[],"yoast_head":"\nSun Pharmaceutical Industries Limited Q2 FY27 Results: Revenue, PAT & Key Highlights | InCred Money<\/title>\n<meta name=\"description\" content=\"Check Sun Pharmaceutical Industries Limited Q2 FY27 quarterly results on InCred Money, including revenue, profit after tax (PAT), year-on-year growth and key financial highlights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sun Pharmaceutical Industries Limited Q2 FY27 Results: Revenue, PAT & Key Highlights | InCred Money\" \/>\n<meta property=\"og:description\" content=\"Check Sun Pharmaceutical Industries Limited Q2 FY27 quarterly results on InCred Money, including revenue, profit after tax (PAT), year-on-year growth and key financial highlights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/\" \/>\n<meta property=\"og:site_name\" content=\"InCred Money\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-30T11:59:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-03T08:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/10\/Sun-Pharma-Q2-FY27-Results.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1301\" \/>\n\t<meta property=\"og:image:height\" content=\"724\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"InCred Money\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"InCred Money\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/\"},\"author\":{\"name\":\"InCred Money\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/#\\\/schema\\\/person\\\/91d1ca8413938f5afdb8971df15afacc\"},\"headline\":\"Sun Pharma Q2 FY27 Results: Revenue, Profit, Sales & Key Updates\",\"datePublished\":\"2026-10-30T11:59:52+00:00\",\"dateModified\":\"2026-11-03T08:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/\"},\"wordCount\":662,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Sun-Pharma-Q2-FY27-Results.jpg\",\"keywords\":[\"Blogs\"],\"articleSection\":[\"Quarterly Results\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/\",\"url\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/\",\"name\":\"Sun Pharmaceutical Industries Limited Q2 FY27 Results: Revenue, PAT & Key Highlights | InCred Money\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Sun-Pharma-Q2-FY27-Results.jpg\",\"datePublished\":\"2026-10-30T11:59:52+00:00\",\"dateModified\":\"2026-11-03T08:33:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/#\\\/schema\\\/person\\\/91d1ca8413938f5afdb8971df15afacc\"},\"description\":\"Check Sun Pharmaceutical Industries Limited Q2 FY27 quarterly results on InCred Money, including revenue, profit after tax (PAT), year-on-year growth and key financial highlights.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Sun-Pharma-Q2-FY27-Results.jpg\",\"contentUrl\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Sun-Pharma-Q2-FY27-Results.jpg\",\"width\":1301,\"height\":724},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/sun-pharmaceutical-industries-quarterly-results-fy27\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sun Pharma Q2 FY27 Results: Revenue, Profit, Sales & Key Updates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/\",\"name\":\"InCred Money\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/#\\\/schema\\\/person\\\/91d1ca8413938f5afdb8971df15afacc\",\"name\":\"InCred Money\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fa3ca621e2126aa06847bfc76570805abd5bcc3be1841b0be0f56d69de3b1d18?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fa3ca621e2126aa06847bfc76570805abd5bcc3be1841b0be0f56d69de3b1d18?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fa3ca621e2126aa06847bfc76570805abd5bcc3be1841b0be0f56d69de3b1d18?s=96&d=mm&r=g\",\"caption\":\"InCred Money\"},\"url\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/author\\\/incred-money-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sun Pharmaceutical Industries Limited Q2 FY27 Results: Revenue, PAT & Key Highlights | InCred Money","description":"Check Sun Pharmaceutical Industries Limited Q2 FY27 quarterly results on InCred Money, including revenue, profit after tax (PAT), year-on-year growth and key financial highlights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/","og_locale":"en_US","og_type":"article","og_title":"Sun Pharmaceutical Industries Limited Q2 FY27 Results: Revenue, PAT & Key Highlights | InCred Money","og_description":"Check Sun Pharmaceutical Industries Limited Q2 FY27 quarterly results on InCred Money, including revenue, profit after tax (PAT), year-on-year growth and key financial highlights.","og_url":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/","og_site_name":"InCred Money","article_published_time":"2026-10-30T11:59:52+00:00","article_modified_time":"2026-11-03T08:33:24+00:00","og_image":[{"width":1301,"height":724,"url":"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/10\/Sun-Pharma-Q2-FY27-Results.jpg","type":"image\/jpeg"}],"author":"InCred Money","twitter_card":"summary_large_image","twitter_misc":{"Written by":"InCred Money","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/#article","isPartOf":{"@id":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/"},"author":{"name":"InCred Money","@id":"https:\/\/www.incredmoney.com\/blog\/#\/schema\/person\/91d1ca8413938f5afdb8971df15afacc"},"headline":"Sun Pharma Q2 FY27 Results: Revenue, Profit, Sales & Key Updates","datePublished":"2026-10-30T11:59:52+00:00","dateModified":"2026-11-03T08:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/"},"wordCount":662,"commentCount":0,"image":{"@id":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/10\/Sun-Pharma-Q2-FY27-Results.jpg","keywords":["Blogs"],"articleSection":["Quarterly Results"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/","url":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/","name":"Sun Pharmaceutical Industries Limited Q2 FY27 Results: Revenue, PAT & Key Highlights | InCred Money","isPartOf":{"@id":"https:\/\/www.incredmoney.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/#primaryimage"},"image":{"@id":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/10\/Sun-Pharma-Q2-FY27-Results.jpg","datePublished":"2026-10-30T11:59:52+00:00","dateModified":"2026-11-03T08:33:24+00:00","author":{"@id":"https:\/\/www.incredmoney.com\/blog\/#\/schema\/person\/91d1ca8413938f5afdb8971df15afacc"},"description":"Check Sun Pharmaceutical Industries Limited Q2 FY27 quarterly results on InCred Money, including revenue, profit after tax (PAT), year-on-year growth and key financial highlights.","breadcrumb":{"@id":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/#primaryimage","url":"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/10\/Sun-Pharma-Q2-FY27-Results.jpg","contentUrl":"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/10\/Sun-Pharma-Q2-FY27-Results.jpg","width":1301,"height":724},{"@type":"BreadcrumbList","@id":"https:\/\/www.incredmoney.com\/blog\/sun-pharmaceutical-industries-quarterly-results-fy27\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.incredmoney.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Sun Pharma Q2 FY27 Results: Revenue, Profit, Sales & Key Updates"}]},{"@type":"WebSite","@id":"https:\/\/www.incredmoney.com\/blog\/#website","url":"https:\/\/www.incredmoney.com\/blog\/","name":"InCred Money","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.incredmoney.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.incredmoney.com\/blog\/#\/schema\/person\/91d1ca8413938f5afdb8971df15afacc","name":"InCred Money","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/fa3ca621e2126aa06847bfc76570805abd5bcc3be1841b0be0f56d69de3b1d18?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fa3ca621e2126aa06847bfc76570805abd5bcc3be1841b0be0f56d69de3b1d18?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fa3ca621e2126aa06847bfc76570805abd5bcc3be1841b0be0f56d69de3b1d18?s=96&d=mm&r=g","caption":"InCred Money"},"url":"https:\/\/www.incredmoney.com\/blog\/author\/incred-money-team\/"}]}},"_links":{"self":[{"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/posts\/15436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/comments?post=15436"}],"version-history":[{"count":1,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/posts\/15436\/revisions"}],"predecessor-version":[{"id":15437,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/posts\/15436\/revisions\/15437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/media\/15457"}],"wp:attachment":[{"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/media?parent=15436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/categories?post=15436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/tags?post=15436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}